BioHealth News
TEDCO Invests in Irazú Oncology
Life sciences company developing a cost-effective production process for cancer immunotherapies COLUMBIA, Md., (March 5, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a…
Read More
REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases
ROCKVILLE, Md., March 4, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced strategic partnership with Nippon Shinyaku. Under the terms of the…
Read More
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer’s and Dementia Detection
POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence…
Read More
GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today an indication expansion for its industry leading…
Read More
Venture Valkyrie: Tough Love for Women’s Health Entrepreneurs Raising Venture Money
Since I have been raising and deploying a venture fund focused on addressing health of women lately, I have had numerous occasions to be in rooms…
Read More
BioBuzz: TEDCO’s Impact on Maryland’s Entrepreneurial Ecosystem
By Annabel Baldy - In November’s What’s the Buzz?! LinkedIn Live session, Chris Frew, CEO of BioBuzz and Tammi Thomas, Chief Development & Marketing Officer, TEDCO…
Read More
GEN: Former NIH Director Francis Collins Praises the Institution as He Abruptly Departs After Three Decades
By Kevin Davies, PhD - March 3, 2025 - After an illustrious career including 12 years as director of the National Institutes of Health…
Read More
GEN: FDA Accepts for Review Precigen RRP Gene Therapy Candidate
By Alex Philippidis - February 26, 2025 - The FDA has granted Priority Review to Precigen’s Biologics License Application (BLA) for its lead candidate…
Read More
TNF Pharmaceuticals Launches Phase 2b Trial for First Oral TNF-Alpha Inhibitor to Combat Muscle Loss and Frailty
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory…
Read More
CityBiz – Protenus: From Accelerator to Acquisition
Protenus, a leading healthcare compliance analytics platform that serves over 200 healthcare organizations, was acquired in January 2025 by Bluesight, a prominent provider of inventory management, procurement,…
Read More
TEDCO Announces Investment in Pathotrak
COLUMBIA, Md., (February 25, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $250,000 Venture Funds investment in Pathotrak. TEDCO’s evergreen…
Read More
NYT: Paying for science
By Benjamin Mueller -The Trump administration stormed into office, loudly firing workers and closing diversity programs. But behind the scenes, it has also brought…
Read More
Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment
ANNAPOLIS, Md., Feb. 19, 2025 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Food and Drug Administration (FDA) has…
Read More
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced it is in the final stages for the launch of its 212-patient Confirmatory Registration Study for Multikine*…
Read More
Britecyte’s Adipose Tissue Allograft Earns “Safe to Proceed” Status from FDA
GERMANTOWN, Md.--(BUSINESS WIRE)--Amarex today announced its work on behalf of Britecyte has resulted in a “safe to proceed” status by the United States Food…
Read More